Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma

Paraganglioma Clinical Trial

— VIBRaNT  

Official title:

A Phase I Trial of Vandetanib Combined With 131I-mIBG Radiotherapy in Patients With Neuroendocrine Tumours, Advanced Phaeochromocytoma and Paraganglioma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01941849
• Other study ID #: UCL/12/0499
• Status: Withdrawn
• Phase: Phase 1
• First received: September 10, 2013
• Last updated: December 18, 2015
• Start date: October 2014
• Est. completion date: December 2015

Study information

• Verified date: December 2015
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: National Health ServiceUnited Kingdom: National Institute for Health ResearchUnited Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The phase I trial aims to determine the recommended phase II dose (RP2D) of vandetanib in combination with standard radiation therapy, 131I-mIBG, in patients with advanced phaeochromocytoma (phaeo) and paraganglioma (PG) by assessing the safety and tolerability of the combination treatment.

Description:

VIBRaNT is a registered phase I trial in patients with locally advanced or metastatic phaeochromocytoma or paraganglioma, not amenable to surgical resection.

Patients will receive vandetanib (an inhibitor of VEGF, EGFR and RET tyrosine kinase) in combination with standard radiation therapy Iodine-131 labelled Meta-iodobenzylguanidine (131I-mIBG).

Vandetanib and 131I-mIBG will be given in 12-weekly cycles: 131I-miBG will be given on day 1 of each cycle and vandetanib will started on day 1 of each cycle and continue to be taken once every day. The phase I trial aims to determine with recommended phase II dose of vandetanib (either 100, 200 or 300 mg once daily) - the dose of vandetanib that patients will receive will depend on the dose under investigation at the time of patient registration.

The vandetanib dose will be determined by the Modified Continual Reassessment Method (mCRM)

• a toxicity model which described the probability of a toxicity occurring at each dose level, which is based on clinical judgement and any available toxicity data.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histopathological/cytological diagnosis of advanced phaeo/PG defined as patients with local or metastatic disease not amenable to surgical resection, or R1 resection post original surgical debulking

2. Positive 123I-mIBG diagnostic scan

3. Stable blood pressure (<140/90mmHg), if appropriate, on anti-hypertensive therapy

4. No previous systemic chemotherapy within 3 months prior to registration

5. No previous mIBG therapy within 12 months prior to registration (previous cumulative activity must not exceed 15 GBq)

6. Measurable disease (RECIST v1.1)

7. WHO performance status 0 or 1

8. Age = 18

9. Estimated life expectancy > 3 months.

10. Adequate bone marrow function: Haemoglobin = 100 g/L, White Blood Cell = 3.0 x 10^9/L, Absolute neutrophil = 1.5 x 10^9/L, Platelet = 100 x 10^9/L

11. Adequate liver function: Total bilirubin =1.5 x Upper Limit of Normal (ULN); ALT/AST and ALP= 2.5 x ULN or = 5 x ULN if related to liver metastases

12. Adequate renal function: Serum urea and creatinine < 1.5x ULN AND Calculated creatinine clearance (GFR) =50 mL/min. If the calculated GFR is below 50, isotope clearance test is required to confirm GFR =50 mL/min

13. Electrolytes: Potassium = 4.0 mmol/L and = 5.5 mmol/L, Magnesium = Lower Limit of Normal and = 1.23 mmol/L, Corrected calcium within institution normal range

14. Negative pregnancy test for women of child-bearing potential AND be using adequate barrier contraception, which must be continued for 12 months after completion of treatment (male patients must also agree to use barrier contraception during the trial and for 12 months after completion of treatment)

15. Able to swallow oral medication

16. Capable of giving written informed consent

Exclusion Criteria:

1. Patients undergoing current treatment with curative intent

2. Previous or current malignancies of other histological types within the last 5 years (exceptions listed in the trial protocol)

3. Any prior exposure to VEGF, EGFR or RET inhibitors or history of hypersensitivity to vandetanib or any excipient agents

4. Evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial

5. Evidence of active uncontrolled infection (patients on antibiotics are eligible)

6. Chronic gastrointestinal disease (e.g. Inflammatory Bowel Disease) or significant bowel resection that would preclude adequate absorption

7. Cardiovascular exclusion criteria (complete list provided in the trial protocol):

• Significant cardiac event (myocardial infarction), New York Heart Association Class II or above, within 12 weeks before registration, or presence of cardiac disease that in the opinion of the investigator increased the risk of ventricular arrhythmia

• Prior or current cardiomyopathy

• Baseline LVEF < 40% as measured by ECHO/MUGA

• Atrial fibrillation with heart rate >100 bpm

• Unstable ischaemic heart disease (myocardial infarction within 6 months prior to starting treatment, or angina requiring use of nitrates more than once weekly)

• History of arrhythmia that was symptomatic or required treatment

• QTcB prolongation >480 ms at baseline

• QT prolongation with other medications that required discontinuation of that medication

8. Any psychiatric or other disorder likely to impact on informed consent or ability to manage isolation

9. Major surgery within 28 days prior to registration

10. Brain metastases or spinal cord compression, unless treated at least four weeks before the first dose and stable without steroid treatment for 10 days

11. Any concomitant medications that may affect QTc, induce or inhibit CYP3A4 function (with the exception of somatostatin or somatostatin analogue) and/or prohibited medications

12. Women who are pregnant or lactating

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoid Tumor
• Neuroendocrine Tumors
• Paraganglioma
• Phaeochromocytoma
• Pheochromocytoma

Intervention

Drug:
• Vandetanib
100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle

Radiation:
• 131I-mIBG
Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)

Locations

Country	Name	City	State
United Kingdom	Guy's and St Thomas' NHS Foundation Trust	London
United Kingdom	The Christie NHS Foundation Trust	London
United Kingdom	University College London Hospitals NHS Foundation Trust	London

Sponsors (3)

Lead Sponsor	Collaborator
University College, London	AstraZeneca, Cancer Research UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of Dose Limiting Toxicity	Detailed adverse event monitoring will be conducted according to CTCAE v4.03. Dose Limiting Toxicity (DLT) is defined as any adverse event or laboratory abnormality detailed in the trial protocol, that is considered to be highly probable or probable trial treatment related and commencing anytime during the DLT evaluation period (from start of cycle 1 to cycle 1 week 12). Adverse Events include: Haematological, Clinical Chemistry, Cardiovascular, Gastrointestinal, Skin.	From start of cycle 1 to end of cycle 1 (each cycle = 12 weeks)	Yes
Secondary	Objective response	Response will be assessed according to RECIST v1.1. Confirmation of complete or partial response is not required. Stable disease will be considered the best response only is a second assessment has been carried out which confirmed stable disease at least 4 weeks after trial entry. Assessment will be determined using CT scans and 123I-mIBG scans performed at baseline, then every 3 months after start of treatment until disease progression (up to 3 years from registration)	Determined using imaging scans performed at baseline (registration), then every 3 months after start of treatment until disease progression up to 3 years from date of registration	No
Secondary	Occurrence and Severity of Adverse Events	Will include all grade 1-5 adverse events.	From date of registration until 30 days after completion of trial treatment (vandetanib and/or 131I-mIBG)	Yes
Secondary	Progression Free Survival	Progression-free survival will be calculated from the date of trial entry to the date of documented disease progression, or death from any cause. Where progression is suspected and subsequently confirmed by scans, the date of documented suspected progression will be used.	From date of registration to date of documented disease progression or death from any cause, whichever comes first, assessed up to 3 years from date of registration	No